Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Agenus Inc. (NASDAQ:AGEN - Get Free Report) have earned a consensus recommendation of "Hold" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.75.

A number of brokerages have recently issued reports on AGEN. B. Riley reiterated a "buy" rating on shares of Agenus in a research report on Monday. Robert W. Baird lowered their target price on Agenus from $6.00 to $3.00 and set a "neutral" rating for the company in a research note on Wednesday, March 12th. StockNews.com raised Agenus from a "sell" rating to a "hold" rating in a research note on Friday, March 21st. Finally, HC Wainwright reissued a "neutral" rating on shares of Agenus in a report on Tuesday, March 18th.

Agenus Price Performance

Shares of NASDAQ AGEN traded down $0.08 during mid-day trading on Friday, hitting $2.78. The company had a trading volume of 148,301 shares, compared to its average volume of 602,668. Agenus has a 12 month low of $1.38 and a 12 month high of $19.69. The firm has a market cap of $70.23 million, a P/E ratio of -0.25 and a beta of 1.58. The business's 50-day simple moving average is $2.16 and its 200-day simple moving average is $3.07.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, beating the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. As a group, sell-side analysts predict that Agenus will post -12.55 EPS for the current year.

Institutional Trading of Agenus

Several large investors have recently made changes to their positions in the company. B. Riley Financial Inc. bought a new position in Agenus in the 4th quarter valued at approximately $2,074,000. Gilead Sciences Inc. acquired a new position in Agenus in the 4th quarter worth about $635,000. Jane Street Group LLC raised its position in Agenus by 97.6% in the fourth quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company's stock valued at $290,000 after purchasing an additional 52,215 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Agenus by 538.4% during the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company's stock valued at $168,000 after purchasing an additional 51,566 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company's stock worth $2,648,000 after purchasing an additional 32,016 shares during the last quarter. Institutional investors and hedge funds own 61.46% of the company's stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.